These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 29577691)

  • 1. [Detection of KRAS mutation in colorectal cancer patients' cfDNA with droplet digital PCR].
    Luo Y; Li Y
    Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):407-420. PubMed ID: 29577691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
    Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
    Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection of mutations in circulating cell-free DNA in relation to disease stage in colorectal cancer.
    Liebs S; Keilholz U; Kehler I; Schweiger C; Haybäck J; Nonnenmacher A
    Cancer Med; 2019 Jul; 8(8):3761-3769. PubMed ID: 31134762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analytical and clinical validation of a novel amplicon-based NGS assay for the evaluation of circulating tumor DNA in metastatic colorectal cancer patients.
    Wang B; Wu S; Huang F; Shen M; Jiang H; Yu Y; Yu Q; Yang Y; Zhao Y; Zhou Y; Pan B; Liu T; Guo W
    Clin Chem Lab Med; 2019 Sep; 57(10):1501-1510. PubMed ID: 31339850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction.
    Janku F; Huang HJ; Fujii T; Shelton DN; Madwani K; Fu S; Tsimberidou AM; Piha-Paul SA; Wheler JJ; Zinner RG; Naing A; Hong DS; Karp DD; Cabrilo G; Kopetz ES; Subbiah V; Luthra R; Kee BK; Eng C; Morris VK; Karlin-Neumann GA; Meric-Bernstam F
    Ann Oncol; 2017 Mar; 28(3):642-650. PubMed ID: 27993791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and Clinical Validation of Discriminatory Multitarget Digital Droplet PCR Assays for the Detection of Hot Spot KRAS and NRAS Mutations in Cell-Free DNA.
    Hussung S; Follo M; Klar RFU; Michalczyk S; Fritsch K; Nollmann F; Hipp J; Duyster J; Scherer F; von Bubnoff N; Boerries M; Wittel U; Fritsch RM
    J Mol Diagn; 2020 Jul; 22(7):943-956. PubMed ID: 32376474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of digital PCR systems for the analysis of liquid biopsy samples of patients affected by lung and colorectal cancer.
    Crucitta S; Ruglioni M; Novi C; Manganiello M; Arici R; Petrini I; Pardini E; Cucchiara F; Marmorino F; Cremolini C; Fogli S; Danesi R; Del Re M
    Clin Chim Acta; 2023 Feb; 541():117239. PubMed ID: 36736684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of Somatic Mutations with ddPCR from Liquid Biopsy of Colorectal Cancer Patients.
    Zmrzljak UP; Košir R; Krivokapić Z; Radojković D; Nikolić A
    Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33669856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
    Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
    Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chemotherapy-associated clonal hematopoiesis mutations should be taken seriously in plasma cell-free DNA KRAS/NRAS/BRAF genotyping for metastatic colorectal cancer.
    Huang F; Yang Y; Chen X; Jiang H; Wang H; Shen M; Yu Y; Liu T; Pan B; Wang B; Guo W
    Clin Biochem; 2021 Jun; 92():46-53. PubMed ID: 33737000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Applying Standard Clinical Chemistry Assay Validation to Droplet Digital PCR Quantitative Liquid Biopsy Testing.
    Milosevic D; Mills JR; Campion MB; Vidal-Folch N; Voss JS; Halling KC; Highsmith WE; Liu MC; Kipp BR; Grebe SKG
    Clin Chem; 2018 Dec; 64(12):1732-1742. PubMed ID: 30237149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the quantification of KRAS mutations by digital PCR and E-ice-COLD-PCR in circulating-cell-free DNA from metastatic colorectal cancer patients.
    Sefrioui D; Mauger F; Leclere L; Beaussire L; Di Fiore F; Deleuze JF; Sarafan-Vasseur N; Tost J
    Clin Chim Acta; 2017 Feb; 465():1-4. PubMed ID: 27940131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Comparison of real-time PCR-optimized oligonucleotide probe method and Sanger sequencing for detection of KRAS mutations in colorectal and lung carcinomas].
    Qiu T; Ling Y; Chen Z; Shan L; Guo L; Lü N; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2012 Sep; 41(9):599-602. PubMed ID: 23157827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The diagnostic accuracy of circulating free DNA for the detection of KRAS mutation status in colorectal cancer: A meta-analysis.
    Xie W; Xie L; Song X
    Cancer Med; 2019 Mar; 8(3):1218-1231. PubMed ID: 30791218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients.
    Hosoya K; Matsusaka S; Kashiwada T; Suzuki K; Ureshino N; Sato A; Miki Y; Kitera K; Hirai M; Hatake K; Kimura S; Sueoka-Aragane N
    Pathol Oncol Res; 2017 Oct; 23(4):737-744. PubMed ID: 28058585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of four platforms for KRAS mutation detection in plasma cell-free DNA: ddPCR, Idylla, COBAS z480 and BEAMing.
    Vessies DCL; Greuter MJE; van Rooijen KL; Linders TC; Lanfermeijer M; Ramkisoensing KL; Meijer GA; Koopman M; Coupé VMH; Vink GR; Fijneman RJA; van den Broek D
    Sci Rep; 2020 May; 10(1):8122. PubMed ID: 32415199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Highly Verified Assay for KRAS Mutation Detection in Tissue and Plasma of Lung, Colorectal, and Pancreatic Cancer.
    Li J; Gan S; Blair A; Min K; Rehage T; Hoeppner C; Halait H; Brophy VH
    Arch Pathol Lab Med; 2019 Feb; 143(2):183-189. PubMed ID: 30088781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective blinded study of somatic mutation detection in cell-free DNA utilizing a targeted 54-gene next generation sequencing panel in metastatic solid tumor patients.
    Kim ST; Lee WS; Lanman RB; Mortimer S; Zill OA; Kim KM; Jang KT; Kim SH; Park SH; Park JO; Park YS; Lim HY; Eltoukhy H; Kang WK; Lee WY; Kim HC; Park K; Lee J; Talasaz A
    Oncotarget; 2015 Nov; 6(37):40360-9. PubMed ID: 26452027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers.
    Möhrmann L; Huang HJ; Hong DS; Tsimberidou AM; Fu S; Piha-Paul SA; Subbiah V; Karp DD; Naing A; Krug A; Enderle D; Priewasser T; Noerholm M; Eitan E; Coticchia C; Stoll G; Jordan LM; Eng C; Kopetz ES; Skog J; Meric-Bernstam F; Janku F
    Clin Cancer Res; 2018 Jan; 24(1):181-188. PubMed ID: 29051321
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.